Definium Therapeutics, Inc. (NASDAQ:DFTX) Given Average Recommendation of “Buy” by Brokerages

Definium Therapeutics, Inc. (NASDAQ:DFTX) has received a consensus rating of “Buy” from the twelve ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, nine have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $35.2222.

DFTX has been the topic of several analyst reports. Chardan Capital raised Definium Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 19th. Needham & Company LLC reiterated a “buy” rating on shares of Definium Therapeutics in a research report on Monday, January 5th. Royal Bank Of Canada lifted their price objective on shares of Definium Therapeutics from $20.00 to $36.00 and gave the stock an “outperform” rating in a research note on Friday, January 23rd. Canaccord Genuity Group upped their target price on shares of Definium Therapeutics from $16.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Finally, Jefferies Financial Group assumed coverage on shares of Definium Therapeutics in a report on Thursday, January 29th. They issued a “buy” rating and a $30.00 target price on the stock.

Definium Therapeutics Stock Performance

Shares of Definium Therapeutics stock opened at $17.13 on Friday. The firm has a fifty day moving average of $15.16 and a two-hundred day moving average of $12.55. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.30 and a current ratio of 3.30. The stock has a market capitalization of $1.69 billion, a price-to-earnings ratio of -8.40 and a beta of 2.57. Definium Therapeutics has a 52 week low of $4.70 and a 52 week high of $18.70.

Insider Buying and Selling

In other Definium Therapeutics news, CEO Robert Barrow sold 25,791 shares of the stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $339,151.65. Following the completion of the sale, the chief executive officer directly owned 778,477 shares in the company, valued at $10,236,972.55. This represents a 3.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mark Sullivan sold 11,276 shares of Definium Therapeutics stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $148,279.40. Following the transaction, the insider owned 282,576 shares in the company, valued at $3,715,874.40. This trade represents a 3.84% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 42,667 shares of company stock valued at $561,071. 2.26% of the stock is owned by company insiders.

Institutional Trading of Definium Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Stoneridge Investment Partners LLC boosted its holdings in shares of Definium Therapeutics by 7.5% in the third quarter. Stoneridge Investment Partners LLC now owns 11,563 shares of the company’s stock valued at $136,000 after buying an additional 804 shares during the period. Cerity Partners LLC lifted its position in Definium Therapeutics by 2.4% in the 2nd quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock valued at $322,000 after acquiring an additional 1,165 shares in the last quarter. Teacher Retirement System of Texas boosted its stake in Definium Therapeutics by 9.4% in the 2nd quarter. Teacher Retirement System of Texas now owns 16,260 shares of the company’s stock worth $106,000 after purchasing an additional 1,400 shares during the period. Creative Planning increased its holdings in Definium Therapeutics by 2.6% during the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after purchasing an additional 1,655 shares in the last quarter. Finally, CWM LLC raised its stake in shares of Definium Therapeutics by 67.4% in the 2nd quarter. CWM LLC now owns 4,459 shares of the company’s stock valued at $29,000 after purchasing an additional 1,796 shares during the period. 27.91% of the stock is currently owned by institutional investors and hedge funds.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.